Table IV.
Effects of ISO treatment on the renal inflammatory mediators.
| Treatment | TNF-α, pg/ml | IL-1β, pg/ml | IL-6, pg/ml | ICAM-1, pg/ml | TGF-β1, pg/ml |
|---|---|---|---|---|---|
| Control | 34.07±5.44 | 51.16±8.10 | 25.03±4.15 | 41.05±6.32 | 67.71±9.45 |
| DM | 90.11±11.20a | 132.07±16.39a | 65.34±8.27a | 96.17±12.85a | 212.53±30.36a |
| ISO-50 | 66.19±8.07b | 100.29±12.24b | 50.37±6.01b | 73.54±8.35b | 152.96±21.88b |
| ISO-150 | 49.58±6.21b,c | 76.44±9.89b,c | 38.03±4.14b,c | 56.62±6.98b,c | 117.51±15.30b,c |
Data are expressed as mean ± standard deviation. P<0.05 vs.
a
control
b
DM; and
c
ISO-50 groups. TNF-α, tumor necrosis factor-α; IL, interleukin; ICAM-1, intercellular adhesion molecule-1; TGF-β1, transforming growth factor-β1; DM, diabetes mellitus; ISO-50, 50 mg/kg/day isorhamnetin; ISO-150, 150 mg/kg/day isorhamnetin.